T1	p 216 272	44 patients with inclusion body myositis in a randomized
T2	i 59 67	myositis
T3	i 90 115	methotrexate or placebo .
T4	i 145 149	20mg
T5	i 154 176	week oral methotrexate
T6	i 286 304	placebo-controlled
T7	i 525 537	methotrexate
T8	i 553 560	placebo
T9	i 840 852	methotrexate
T10	i 883 895	methotrexate
T11	o 20 40	weakness progression
T12	o 332 389	change of quantitative muscle strength testing sum scores
T13	o 430 486	Quantitative muscle strength testing sum scores declined
T14	o 660 731	manual muscle testing sum scores , activity scale scores and patients '
T15	o 778 818	Serum creatine kinase activity decreased
T16	o 929 944	muscle weakness
T17	o 959 991	serum creatine kinase activity .